CD226 and rheumatoid arthritis: Although DNAM-1 variants are described as susceptibility genes for developing RA [22,24], DNAM-1 neutralizing antibody treatment or DNAM-1 deficiency in the collagen-induced arthritis (CIA) mouse model of RA did not affect disease development nor severity [70].